Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2022

View Archived Issues

S100A4 levels correlate with active eosinophilic esophagitis

IL13RA1 is a therapeutic target in the treatment of EoE

New complement factor B inhibitors identified at Shanghai Meiyue Biotech Development

PROTACs targeting IRAK-4 synthesized at Shanghai Leadingtac Pharmaceutical

Kira Pharmaceuticals discovers C5aR antagonists

BeiGene divulges new G12C mutant GTPase KRAS inhibitors

Beijing Tide Pharmaceutical patents son of sevenless homolog 1 inhibitors

Fibulin-2 as a novel therapeutic target in multiple sclerosis

Study finds potential entry points to Huntington's therapy

Targeting MRGPRX2-mediated mast cell activation as a therapeutic strategy for atopic dermatitis

Discovery of novel orally bioavailable inhibitors of EGFR T790M/C797S mutants

ANGPTL4 is elevated in peanut allergy

Tonix enters research agreement with Inserm to study oxytocin in Prader-Willi syndrome mouse model

PBI-0451 shows promising results for the treatment of COVID-19

SpFN_1B-06-PL vaccine induces durable immune response against pathogens

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...